📊 LLY Key Takeaways
Is ELI LILLY & Co (LLY) a Good Investment?
Eli Lilly demonstrates exceptional fundamental strength with 44.7% revenue growth and nearly doubling net income (94.9% YoY), indicating robust demand for its pharmaceutical products. The company maintains impressive profitability metrics with 39.5% operating margin and 31.7% net margin while generating strong free cash flow of $15.5B, positioning it to sustain R&D investments and shareholder returns. Financial health is solid with manageable debt leverage (1.54x D/E), exceptional interest coverage (143.3x), and adequate liquidity despite high long-term debt.
Eli Lilly’s fundamentals are exceptionally strong, with 44.7% revenue growth, 94.9% net income growth, and very high operating and net margins, indicating that recent growth is translating efficiently into profits. Cash generation is robust, with $15.46B of free cash flow and excellent interest coverage, supporting reinvestment and financial flexibility. The main constraint on an even more aggressive rating is elevated leverage and the need to prove that current growth can remain durable rather than peak-driven.
Why Buy ELI LILLY & Co Stock? LLY Key Strengths
- Exceptional revenue growth of 44.7% YoY driven by strong pharmaceutical demand
- Outstanding profitability with 31.7% net margin and 39.5% operating margin
- Exceptional shareholder returns with 77.8% ROE and 18.4% ROA
- Strong free cash flow generation of $15.5B representing 23.7% of revenue
- Fortress balance sheet with 143.3x interest coverage ratio providing financial flexibility
- Consistent operational execution evidenced by 26 available metrics and low data gaps
- Exceptional top-line and bottom-line growth with revenue up 44.7% and net income up 94.9% YoY
- Very strong profitability profile with 39.5% operating margin, 31.7% net margin, and 77.8% ROE
- High-quality cash generation with $16.81B operating cash flow, $15.46B free cash flow, and 143.3x interest coverage
LLY Stock Risks: ELI LILLY & Co Investment Risks
- High leverage with 1.54x debt-to-equity ratio and $40.9B long-term debt requiring debt service discipline
- Significant YoY earnings growth (94.9%) may be partially from non-recurring items or one-time events requiring normalization
- Pharmaceutical sector faces regulatory risks, patent expirations, and pricing pressure from government and payers
- Heavy reliance on successful product pipeline given mature market and competition from generics
- Debt/equity of 1.54x and $40.87B of long-term debt increase balance-sheet leverage risk
- Pharmaceutical earnings can be vulnerable to product concentration, patent cliffs, and regulatory setbacks
- Rapid recent profit expansion may normalize if growth drivers slow or margins compress
Key Metrics to Watch
- Revenue growth sustainability - monitor if 44.7% growth continues or normalizes
- Operating cash flow trends - verify $16.8B OCF can sustain current capex and debt service
- Debt reduction trajectory - track progress on $40.9B long-term debt given strong FCF
- Gross margin disclosure - currently N/A; need clarity on product mix profitability
- R&D efficiency - ensure growth investments translate to meaningful pipeline advances
- Revenue growth and net margin sustainability
- Free cash flow generation relative to debt levels
ELI LILLY & Co (LLY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 23.7% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
LLY Profit Margin, ROE & Profitability Analysis
LLY vs Healthcare Sector: How ELI LILLY & Co Compares
How ELI LILLY & Co compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ELI LILLY & Co Stock Overvalued? LLY Valuation Analysis 2026
Based on fundamental analysis, ELI LILLY & Co has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ELI LILLY & Co Balance Sheet: LLY Debt, Cash & Liquidity
LLY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: ELI LILLY & Co's revenue has grown significantly by 130% over the 5-year period, indicating strong business expansion. The most recent EPS of $5.80 reflects profitable operations.
LLY Revenue Growth, EPS Growth & YoY Performance
LLY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $11.4B | $970.3M | $1.07 |
| Q2 2025 | $11.3B | $3.0B | $3.28 |
| Q1 2025 | $8.8B | $2.2B | $2.48 |
| Q3 2024 | $9.5B | -$57.4M | $-0.06 |
| Q2 2024 | $8.3B | $1.8B | $1.95 |
| Q1 2024 | $7.0B | $1.3B | $1.49 |
| Q3 2023 | $6.9B | -$57.4M | $-0.06 |
| Q2 2023 | $6.5B | $952.5M | $1.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ELI LILLY & Co Dividends, Buybacks & Capital Allocation
LLY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for ELI LILLY & Co (CIK: 0000059478)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LLY
What is the AI rating for LLY?
ELI LILLY & Co (LLY) has a Combined AI Rating of BUY from Claude (STRONG BUY) and ChatGPT (BUY) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LLY's key strengths?
Claude: Exceptional revenue growth of 44.7% YoY driven by strong pharmaceutical demand. Outstanding profitability with 31.7% net margin and 39.5% operating margin. ChatGPT: Exceptional top-line and bottom-line growth with revenue up 44.7% and net income up 94.9% YoY. Very strong profitability profile with 39.5% operating margin, 31.7% net margin, and 77.8% ROE.
What are the risks of investing in LLY?
Claude: High leverage with 1.54x debt-to-equity ratio and $40.9B long-term debt requiring debt service discipline. Significant YoY earnings growth (94.9%) may be partially from non-recurring items or one-time events requiring normalization. ChatGPT: Debt/equity of 1.54x and $40.87B of long-term debt increase balance-sheet leverage risk. Pharmaceutical earnings can be vulnerable to product concentration, patent cliffs, and regulatory setbacks.
What is LLY's revenue and growth?
ELI LILLY & Co reported revenue of $65.2B.
Does LLY pay dividends?
ELI LILLY & Co pays dividends, with $5,384.0M distributed to shareholders in the trailing twelve months.
Where can I find LLY SEC filings?
Official SEC filings for ELI LILLY & Co (CIK: 0000059478) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LLY's EPS?
ELI LILLY & Co has a diluted EPS of $22.95.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LLY a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, ELI LILLY & Co has a BUY rating with 90% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is LLY stock overvalued or undervalued?
Valuation metrics for LLY: ROE of 77.8% (sector avg: 15%), net margin of 31.7% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy LLY stock in 2026?
Our dual AI analysis gives ELI LILLY & Co a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is LLY's free cash flow?
ELI LILLY & Co's operating cash flow is $16.8B, with capital expenditures of $1.4B. FCF margin is 23.7%.
How does LLY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 31.7% (avg: 12%), ROE 77.8% (avg: 15%), current ratio 1.58 (avg: 2).
Is ELI LILLY & Co carrying too much debt?
LLY has a debt-to-equity ratio of 1.54x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.58 suggests adequate short-term liquidity.
Why is LLY's return on equity (ROE) so high?
ELI LILLY & Co has a return on equity of 77.8%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 31.7% net margin.